The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Morrow, W. J. W.; Williams, Diana; Férec, Claude; R, Casburn-Budd; Isenberg, David; Paice, E. W.; Snaith, M L; Youinou, Pierre; Goff, P. Le

doi:10.1136/ard.42.6.668

Cited by 42 publications

(20 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus in LCV. as in SLE or RA [6][7][8][9][10], C3d,g and TCC appear to be sensitive indicators of systemic eomplement aetivation. Measurements of CH^o in plasma revealed a significant increase in (i5% of lhe patients.…”

Section: Discussionmentioning

confidence: 99%

Local and systemic activationofthe whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers

Dauchel

Joly

Delpech

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARY We have studied complement activation both in plasma samples and In lesional skin from palients with leukocytoclaslic cutaneous vasculitis (LCV). Enzyme immunoassay (EIA) quantification of the complement activation markers. C3d,g and fhe terminal complement complex (TCC) in plasma, showed lhal their levels were significantly increased in 66% and 55% of the patienis, respectively (n = 29) compared with healthy controls, whereas the standard measurements of C3, factor B, Clq, C4and C2 were generally within normal range. Elevations of C3d,g and TCC levels in plasma were signifieantly eorrelated. Importantly, a signifieant correlation was found between the severity of the vasculitis and both C3d,g and TCC plasma levels. Immunofluorescence studies of skin biopsy specimens demonstrated simultaneous presence of peri vascular dermal deposits of C3d,g and TCC in lesional skin from 96 Mi and 80% respectively of the patients (n= 25). There was a significant eorrelation between the intensity of the deposits of bolh markers. Clusterin, a TCC inhibitory protein, was always found at the same sites of perivascular TCC deposits, Immunofluorescence studies at the epidermal basemenl membrane zone (BMZ) revealed in each case deposits of C3d,g which were accompanied by TCC deposits in 52% of the biopsy specimens. These data demonstrate that there is a local and systemic activation of the whole complement cascade in human LCV. The presenee of both C3d,g and clusterin‐associatcd TCC perivascular deposits suggests an intervention of a regulatory mechanism oflocal complement activation in LCV. Einally, measurement of plasma C3d,g and TCC appears to be a sensitive indicator of systemic complement activation and disease severity in LCV.

show abstract

Section: Discussionmentioning

confidence: 99%

Local and systemic activationofthe whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers

Dauchel

Joly

Delpech

et al. 1993

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…The SLE patient group consisted of 74 consecutive SLE patients attending the outpatient clinic of the Department of Rheumatology, Sahlgren University Hospital, Gothenburg, Sweden, who fulfilled four or more of the American Rheumatism Association criteria for SLE (44). With the aim of obtaining patient groups with distinctive degrees of complement activation, these patients were classified according to the system of Morrow et al (36) into one of the following four clinical disease activity groups: inactive, low active, moderately active, and severely active, referred to as SLE grades I, II, III, and IV, respectively. This classification is based on the number of the following symptoms exhibited: arthralgia, myalgia, vasculitis, pleuritis, pericarditis, and cerebral, skin, or renal involvement.…”

Section: Patients and Controls (I)mentioning

confidence: 99%

Use of Serum or Buffer-Changed EDTA-Plasma in a Rapid, Inexpensive, and Easy-To-Perform Hemolytic Complement Assay for Differential Diagnosis of Systemic Lupus Erythematosus and Monitoring of Patients with the Disease

Ekdahl

Norberg

Bengtsson

et al. 2007

Clin Vaccine Immunol

View full text Add to dashboard Cite

We previously described a simplified quantitative hemolytic assay for classical pathway (CP) hemolytic function in serum that has been shown to correlate with the 50% hemolytic complement (CH 50 ) assay. In the present study, we used this assay to compare CP functions; plasma levels of C3, C4, and C3dg; and ratios of C3dg to C3 in healthy individuals and patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) with different degrees of complement activation. A significant depression in CP function and levels of C4 and C3 and increased C3dg levels and C3dg/C3 ratios were observed in the SLE patients. In patients with RA, CP function was normal, whereas C3, C4, and C3dg levels and the C3dg/C3 ratio were elevated. The SLE results are compatible with systemic complement consumption, whereas the RA data suggest an acute-phase reaction with a normal C3 catabolic rate. To facilitate the handling of patient samples, we also developed a method to restore the hemolytic function of EDTA-plasma by transferring it to Veronal-buffered saline containing the thrombin inhibitor lepirudin. This process inhibits coagulation and enables complement activation, allowing a longer time lag between sample harvesting and testing. These results, combined with previous correlation studies, suggest that the CP hemolytic assay can effectively replace the CH 50 assay for routine SLE differential diagnosis and monitoring of disease activity.

show abstract

“…Previous reports using conventional procedures presented different conclusions on the clinical significance of C3 breakdown products in SLE (16,21,22,43). We were able to demonstrate a highly significant correlation with lupus disease activity, however.…”

Section: Discussionmentioning

confidence: 98%

“…The quantitation of C3 fragments in plasma was used previously by several workers to estimate the in vivo activation of the complement system in patients with autoimmune diseases (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25). The assay procedures used in these studies, however, have not been widely applied to the study of autoimmune diseases, perhaps because of the complexity and difficulties of the techniques developed.…”

mentioning

confidence: 99%

The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus

Negoro

Okamura

Takeda

et al. 1989

Arthritis & Rheumatism

View full text Add to dashboard Cite

We studied the expression of an iC3b neoantigen (iC3b-NEO) in plasma from patients with systemic lupus erythematosus (SLE), by using a monoclonal antibody specific for iC3b/C3dg/C3d, to investigate the activation of the third component of complement in SLE. The plasma iC3b-NEO level in 40 untreated patients with active SLE was significantly higher than that in 36 normal subjects (mean & SD 31.5 -t 13.9 pglml versus 12.3 -+ 3.3 pg/ml; P C 0.001). The plasma iC3b-NEO level was highly correlated with clinical disease activity ( 7 = 0.62, P < O.OOOl), and it was the parameter most closely correlated with renal histologic activity in lupus nephritis (T = 0.52, P < 0.0001). Also, patients with diffuse proliferative lupus nephritis had the highest levels of plasma iC3b-NEO among all World Health Organization classes of lupus nephritis (P C 0.01). We conclude that the plasma iC3b-NEO level is strongly associated with clinical disease activity and renal histologic activity in patients with SLE, and that plasma

show abstract

The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Cited by 42 publications

References 9 publications

Local and systemic activationofthe whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers

Local and systemic activationofthe whole complement cascade in human leukocytoclastic cutaneous vasculitis; C3d,g and terminal complement complex as sensitive markers

Use of Serum or Buffer-Changed EDTA-Plasma in a Rapid, Inexpensive, and Easy-To-Perform Hemolytic Complement Assay for Differential Diagnosis of Systemic Lupus Erythematosus and Monitoring of Patients with the Disease

The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus

Contact Info

Product

Resources

About